Bhattacharya Priyanka T, Hameed Asif M Abdul, Bhattacharya Shubhadeep T, Chirinos Julio A, Hwang Wei-Ting, Birati Edo Y, Menachem Jonathan N, Chatterjee Saurav, Giri Jay S, Kawut Steven M, Kimmel Stephen E, Mazurek Jeremy A
Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Pulm Circ. 2020 Nov 23;10(4):2045894020966889. doi: 10.1177/2045894020966889. eCollection 2020 Oct-Dec.
Readmissions for pulmonary hypertension are poorly understood and understudied. We sought to determine national estimates and risk factors for 30-day readmission after pulmonary hypertension-related hospitalizations. We utilized the Healthcare Cost and Utilization Project Nationwide Readmission Database, which has weighted estimates of roughly 35 million discharges in the US. Adult patients with primary International Classification of Disease, Ninth Revision, Clinical Modification diagnosis codes of 416.0 and 416.8 for primary and secondary pulmonary hypertension with an index admission between 2012 and 2014 and any readmission within 30 days of the index event were identified. Predictors of 30-day readmission were identified using multivariable logistic regression with adjustment for covariates. Results showed that the national estimate for Primary Pulmonary Hypertension vs Secondary Pulmonary Hypertension-related index events between 2012 and 2014 with 30-day readmission was 247 vs 2550 corresponding to a national readmission risk estimate of 17% vs 18.3%, respectively. The presence of fluid and electrolyte disorders, renal failure, and alcohol abuse were associated with increased risk of readmission in Primary Pulmonary Hypertension, while factors associated with Secondary Pulmonary Hypertension readmissions included anemia, congestive heart failure, lung disease, fluid and electrolyte disorders, renal failure, diabetes, and liver disease. The median cost of Primary Pulmonary Hypertension admissions and readmissions were $46,132 (IQR: $25,384-$85,647) and $41,604.50 (IQR: $22,481.50-$84,420.50), respectively. The median costs of Secondary Pulmonary Hypertension admissions and readmissions were $34,893 (IQR: $19,670-$66,143) and $36,279 (IQR: $19,059-$74,679), respectively. In conclusion, approximately 19% of Primary Pulmonary Hypertension and Secondary Pulmonary Hypertension hospitalizations result in 30-day readmission, with significant costs accrued during the index hospitalization and readmission. With evolving clinical terminology and diagnostic codes, future study will need to better clarify underlying factors associated with readmissions amongst pulmonary hypertension sub-types, and identify methods and procedures to minimize readmission risk.
肺动脉高压再入院情况目前了解甚少且研究不足。我们试图确定与肺动脉高压相关住院后30天再入院的全国估计数及风险因素。我们使用了医疗保健成本与利用项目全国再入院数据库,该数据库对美国约3500万例出院病例进行了加权估计。确定了2012年至2014年间首次入院时主要国际疾病分类第九版临床修订本诊断代码为416.0和416.8的原发性和继发性肺动脉高压成年患者,以及在首次事件后30天内的任何再入院病例。使用多变量逻辑回归并对协变量进行调整来确定30天再入院的预测因素。结果显示,2012年至2014年间与原发性肺动脉高压和继发性肺动脉高压相关的首次事件且伴有30天再入院的全国估计数分别为247例和2550例,对应的全国再入院风险估计分别为17%和18.3%。原发性肺动脉高压中,存在液体和电解质紊乱、肾衰竭及酒精滥用与再入院风险增加相关,而继发性肺动脉高压再入院相关因素包括贫血、充血性心力衰竭、肺部疾病、液体和电解质紊乱、肾衰竭、糖尿病及肝脏疾病。原发性肺动脉高压入院和再入院的中位费用分别为46,132美元(四分位间距:25,384美元 - 85,647美元)和41,604.50美元(四分位间距:22,481.50美元 - 84,420.50美元)。继发性肺动脉高压入院和再入院的中位费用分别为34,893美元(四分位间距:19,670美元 - 66,143美元)和36,279美元(四分位间距:19,059美元 - 74,679美元)。总之,约19%的原发性肺动脉高压和继发性肺动脉高压住院会导致30天再入院,在首次住院和再入院期间会产生重大费用。随着临床术语和诊断代码的不断演变,未来的研究需要更好地阐明与肺动脉高压亚型再入院相关的潜在因素,并确定将再入院风险降至最低的方法和程序。